secwatch.observer — SEC 8-K summary
======================================

Issuer:     Caribou Biosciences, Inc. (CRBU)
CIK:        0001619856
Form:       8-K
Filed at:   2026-10-06T20:07:10+00:00
Accession:  0001193125-26-415559
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.05, 5.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Caribou Biosciences halts vispa-cel and CB-011 CAR-T programs, cuts workforce, explores strategic alternatives
--------------------------------------------------------------------------------

- Board approved restructuring on Oct 2, 2026 with estimated charges of $15M-$19M: $10M-$11M severance/benefits and $5M-$8M to wind down the ANTLER and CaMMouflage phase 1 trials.
- Majority of affected employees expected to depart in Q4 2026; Board formed a Transaction Committee and engaged Wedbush Securities Inc. as exclusive financial advisor for the strategic review.
- CFO Sriram Ryali's employment terminates upon execution of a binding definitive agreement for a strategic alternative; treated as termination without cause with severance.
- Cash, cash equivalents and marketable securities totaled $113.8M as of June 30, 2026; no timeline set for completing the strategic alternatives review.
- Discontinued programs: vispa-cel for r/r B cell non-Hodgkin lymphoma (pivotal trial-ready, FDA-aligned phase 3 design, RMAT/Fast Track/Orphan designations) and CB-011 for r/r multiple myeloma.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1619856/000119312526415559/0001193125-26-415559-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1619856/000119312526415559/d235175d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-415559

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer